Does Cannabis Help Manage Agitation in Dementia Patients?

PostedMarch 9, 2026

UpdatedMarch 9, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

Agitation is one of the most distressing behavioural symptoms of dementia, often involving restlessness, irritability, and anxiety. Families sometimes ask whether medical cannabis might help calm these symptoms when traditional medications are not effective.

According to NHS guidance and NICE NG144, medical cannabis is only approved in the UK for specific conditions such as severe epilepsy, multiple sclerosis-related spasticity, and chemotherapy-induced nausea. It is not approved for dementia or its behavioural symptoms.

What Research Shows About Cannabis and Agitation

Several small studies have explored whether cannabinoids, including THC, CBD, or combined formulations such as nabiximols (Sativex), can reduce agitation in dementia. Reviews published in the BMJ and PubMed indicate that some participants experienced short-term reductions in agitation or caregiver distress.

However, results have been inconsistent, and improvements were often mild or similar to placebo effects. Adverse reactions such as drowsiness, confusion, and dizziness were common, raising safety concerns for older adults with cognitive impairment.

The UK Regulatory Position

According to Alzheimer’s Society UK and NICE, there is currently insufficient evidence to support prescribing cannabis-based medicines for agitation in dementia. Use is therefore restricted to clinical trials or specialist-led, off-label situations, and routine prescribing is not recommended.

Clinical Bottom Line

Evidence for cannabis in managing agitation in dementia is limited and inconsistent.

NICE and NHS guidance does not recommend routine prescribing for this purpose.

Short-term benefits, when observed, are small and often comparable to placebo.

Side effects such as sedation, confusion, and falls remain significant risks.

Use should only occur under specialist medical supervision or within clinical trials.

About AlleviMed

If you are exploring whether medical cannabis could be suitable for managing symptoms, services such as AlleviMed (launching soon) will provide eligibility consultations. These aim to help patients and families understand whether cannabis-based treatment could be appropriate and lawful under current UK medical regulations.

Takeaway

At present, cannabis cannot be recommended as an effective or safe treatment for agitation in dementia. NICE and NHS guidance emphasise that evidence remains weak, and potential harm may outweigh any modest benefits. Supportive care and non-drug behavioural strategies remain the safest and most effective options.

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.